IL17A and hepatocellular carcinoma: In stark contrast, cumulative evidence indicates that interleukin 17 (IL-17)–producing γδ (γδ17) T cells promote tumor progression in several experimental models, including a genetic mouse model of pancreatic intraepithelial neoplasia [7]; transplantable models of subcutaneous fibrosarcoma, skin carcinoma, and colon cancer [8]; subcutaneous and intrahepatic hepatocellular carcinoma [9]; as well as intraperitoneal ovarian cancer [10].